Antitumor Effects of Analogs of Hypothalamic Hormones in Endocrine-Dependent Cancers

Schally, Andrew V.; Comaru‐Schally, Ana Maria; Redding, Tommie W.

doi:10.3181/00379727-175-41797

Cited by 132 publications

(110 citation statements)

References 51 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…Several studies have explored the potential role of GNRH in extrapituitary tissues, starting from the observation that GNRH analogs can inhibit the growth of nonpituitary tumor cell lines (22). In addition to being expressed in the pituitary gland, the receptor for GNRH is found in various tissues of the reproductive system (the breast, endometrium, ovary, and prostate), in tumors derived from these tissues, and in lymphocytes.…”

Section: Discussionmentioning

confidence: 99%

A case of primary aldosteronism in pregnancy: do LH and GNRH receptors have a potential role in regulating aldosterone secretion?

Albiger¹,

Sartorato²,

Mariniello³

et al. 2011

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: The mechanisms inducing steroidogenesis in primary aldosteronism (PA) remain poorly defined. It was recently demonstrated that some G-protein-coupled receptors are abnormally expressed in aldosterone-producing adenomas (APA). We evaluated the potential role of LH and GNRH receptors (LHR (or LHCGR) and GNRHR) in regulating aldosterone secretion in a patient with APA arising during pregnancy (index case) and in a subset of other patients with PA. Patients and methods: GNRH test was performed in the index case, 11 other PA, and 5 controls. GNRHR and LHR expressions were examined in 23 APA and 6 normal tissues. Results: Aldosterone response increased significantly (114%) in the index case after GNRH test was performed preoperatively, while it was blunted after adrenalectomy. Aldosterone also increased after human chorionic gonadotropin and triptorelin stimulation. A partial aldosterone response to GNRH was observed in other 7/11 PA, while a significant response was observed in two patients. Controls did not respond to GNRH test. GNRHR was overexpressed and LHR expression was moderate in the APA tissue from the index case. Moreover, LHR was found in normal adrenals and overexpressed in 6/22 APA. GNRHR was overexpressed in 6/22 APA, 2 of them with a 95-and 109-fold higher expression than normal. A correlation between the clinical and molecular findings was observed in five out of seven patients. Conclusion: We describe a case of PA diagnosed during pregnancy, which appeared to correlate with aberrant LHR and GNRHR expression. Our findings suggest that a subset of patients with PA has aberrant LHR and GNRHR expression, which could modulate aldosterone secretion.

show abstract

Section: Discussionmentioning

confidence: 99%

A case of primary aldosteronism in pregnancy: do LH and GNRH receptors have a potential role in regulating aldosterone secretion?

Albiger¹,

Sartorato²,

Mariniello³

et al. 2011

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

“…Chronic administration of potent LH-RH agonists leads to the inhibition of pituitary and gonadal functions (2)(3)(4)(5)(6). While repeated administration of LH-RH agonists is required to lower the levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and sex steroids, similar effects can be obtained with single administration of LH-RH antagonists (7). Competitive antagonists of LH-RH were developed by multiple modification of the parent molecule, <Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-ProGly-NH2 (8)(9)(10)(11)(12)(13)(14) (<Glu, pyroglutamic acid).…”

mentioning

confidence: 99%

Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects.

Bajusz¹,

Kovács²,

Gazdag³

et al. 1988

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

To eliminate the undesirable edematogenic effect of the lutemizing hormone-releasing hormone (LH- Since the isolation and structural elucidation of hypothalamic luteinizing hormone-releasing hormone (LH-RH) more than 2000 analogs have been synthesized, in view of their expected medical applications (1). Chronic administration of potent LH-RH agonists leads to the inhibition of pituitary and gonadal functions (2-6). While repeated administration of LH-RH agonists is required to lower the levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and sex steroids, similar effects can be obtained with single administration of LH-RH antagonists (7). Competitive antagonists of LH-RH were developed by multiple modification of the parent molecule,

show abstract

“…3 (2,3,(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34). The therapy based on agonists of LH-RH avoids the cardiovascular and mammotropic side effects of estrogens and the psychological impact of orchiectomy (22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36). It has been suggested that treatment with [D-Trp6]LH-RH produces a higher rate of response than transcapsular orchiectomy (35).…”

mentioning

confidence: 99%

“…It has been suggested that treatment with [D-Trp6]LH-RH produces a higher rate of response than transcapsular orchiectomy (35). The use of LH-RH agonists may be the method of choice for the treatment ofprostate cancer (3,(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36) been used successfully for the treatment of women with endometriosis (37) and children with precocious puberty (38). However, the duration of response and the median survival time in patients with prostate cancer cannot yet be estimated.…”

mentioning

confidence: 99%

Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.

Schally¹,

Kook²,

Monje³

et al. 1986

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

Antitumor Effects of Analogs of Hypothalamic Hormones in Endocrine-Dependent Cancers

Cited by 132 publications

References 51 publications

A case of primary aldosteronism in pregnancy: do LH and GNRH receptors have a potential role in regulating aldosterone secretion?

A case of primary aldosteronism in pregnancy: do LH and GNRH receptors have a potential role in regulating aldosterone secretion?

Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects.

Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.

Contact Info

Product

Resources

About